NCT03911388View on ClinicalTrials.gov

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2027

Conditions
Neoplasms, BrainGlioblastoma MultiformeGlioblastoma of CerebellumNeoplasmsAstrocytomaAstrocytoma, CerebellarNeuroectodermal TumorsNeuroectodermal Tumors, PrimitiveCerebellar PNET, ChildhoodCerebellar NeoplasmsCerebellar Neoplasms, PrimaryCerebellar Neoplasm, MalignantCerebellar Neoplasm Malignant PrimaryNeoplasm MetastasesNeoplasm MalignantNeoplasms, NeuroepithelialNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Glandular and EpithelialNeoplasms, Nerve TissueCentral Nervous System Neoplasms, PrimaryCentral Nervous System Neoplasms, MalignantNervous System NeoplasmsNeoplasms by SiteBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMedulloblastoma RecurrentHSVVirusPediatric Brain TumorNervous System CancerPrimitive Neuroectodermal Tumor (PNET) of Cerebellum
Interventions
BIOLOGICAL

G207

Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.

Trial Locations (3)

35233

ACTIVE_NOT_RECRUITING

Children's of Alabama, Birmingham

63110

ACTIVE_NOT_RECRUITING

St. Louis Children's Hospital, St Louis

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Cannonball Kids' Cancer Foundation

OTHER

collaborator

Treovir, Inc

UNKNOWN

lead

M.D. Anderson Cancer Center

OTHER